All News

Found 613 articles

• M&A Targets Pfizer and Others Could be Eyeballing

  5/24/2016

• 3 Stocks with Moonshot Potential that are Safer Buys than bluebird bio

  5/4/2016

• Biogen Poaches Star Pfizer Scientist as New R&D Chief

  4/29/2016

• While Exploring Sale of Its Hemophilia Unit, Some Speculate Biogen Might be Prepping to Buy or be Acquired

  4/13/2016

• A Day After The Pfizer-Allergan Deal Dies, Allergan Inks Potential $3.3 Billion Alzheimer’s Deal with Heptares

  4/11/2016

• Nixed Pfallergan Deal Has Investors Wondering if Allergan Might Target Biogen

  4/7/2016

• Why SoCal's Acadia May Be a Perfect Takeover Target for Biogen

  4/5/2016

• Bay Area's XenoPort Snags Psoriasis and MS Deal Worth $490 Million+ from Dr. Reddy's Laboratories Ltd.

  3/28/2016

• Bay State's FORUM Pharma Lays Off 89 After Two Failed Clinical Trials

  3/28/2016

• TauRx Pharma Co-Founder's 30-Year Alzheimer's Quest May Bear Fruit in July

  3/21/2016

• BioPharm Executive: What Gets This Market Back on Track?

  2/24/2016

• Three Dinged Biopharmas that Could Make a Fierce Comeback

  2/17/2016

• Biogen Points Out Three New Risk Factors For 2016 in SEC Filing, Report Shows

  2/9/2016

• Investors Grin Over Biogen's $3.4 Billion Cash Pile and Earnings Report

  1/28/2016

• Biogen's Promising Pipeline Underscores CEO’s High-Risk Strategy

  1/19/2016

• Biogen CMO Says Company Plans To Hire 150 For Neuroscience Development

  1/18/2016

• Pint-Sized Anavex May Soon Have the Data to Prove Biogen and Eli Lilly's Alzheimer's Approach is All Wrong

  12/10/2015

• With $4.1 Billion in Its Pocket, Biogen Might Go Shopping

  12/8/2015

• Who Can Gobble Up Biogen, or Who Can Biogen Buy

  11/17/2015

• After Dropping the "Biogen Bombshell," CEO Turns R&D Focus to Neurological Diseases Like Alzheimer's

  11/13/2015